FDA’s Warning Letter to Empower Pharmacy, Explained
A September 18 FDA warning letter to Empower Pharmacy describes alleged Section 503A failures involving compounded products FDA characterized as copies of marketed semaglutide and tirzepatide products. The action offers a documented view of the agency’s current compounding-enforcement posture.
Read article